RIO DE JANEIRO, BRAZIL - Anvisa (National Health Surveillance Agency) approved on April 25 one more cannabis-based medicinal product in Brazil, the Cannabidiol Active Pharmaceutical. It is the 15th product with commercialization approved in the country.
The product must contain 20 mg/ml of cannabidiol (CBD) and up to 0.2% of tetrahydrocannabinol (THC . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here